Pharmaxis, Ltd. engages in the research, development, and commercialization of human therapeutic products for the diagnosis and treatment of chronic respiratory and inflammatory/autoimmune diseases primarily in Australia. The company's products candidates include Aridol, a proprietary dry powder formulation of mannitol, which has completed Phase III clinical trial and is used for the diagnosis and management of asthma, and chronic obstructive pulmonary disease; Bronchitol, which is under Phase III clinical trial for the treatment of chronic obstructive lung diseases, including cystic fibrosis, bronchiectasis, and chronic bronchitis; PXS25/64 is under pre-clinical toxicology studies for the prevention of inappropriate migration of immune cells from blood to surrounding tissue; and PXS74, a pre-clinical development candidate for the treatment of asthma. It also develops PXS2076 for the treatment of rheumatoid arthritis and neuropathic pain. The company was founded in 1998 as Praxis Pharmaceuticals Australia Pty, Ltd. and changed its name to Pharmaxis Pty, Ltd. in 2002. Further, it changed its name to Pharmaxis, Ltd. in 2003. Pharmaxis is headquartered in Frenchs Forest, Australia.